更昔洛韦在D+/R+肾移植术后预防CMV 感染的疗效观察

目的:观察D+/R+肾移植术后人群应用更昔洛韦预防巨细胞病毒感染的疗效与安全性。方法:我院2003年5月至2011年11月期间D+/R+同种异体肾移植患者93例,肾移植术后预防性应用更昔洛韦,对移植后1年内巨细胞病毒的感染率、感染发生的时间及有症状的CMV发病率进行以及用药后不良事件进行分析。结果:在D+/R+肾移植人群中预防性使用更昔洛韦后的感染率为28%,有症状的CMV发病率4.3%,病毒血症的平均感染时间为231.3 d,严重不良事件发生率为45.1%。结论:在D+/R+肾移植术后患者中预防性更昔洛韦能够预防CMV感染并且延长CMV初次感染时间,使D+/R+肾移植患者获益。

Prophylactic Treatment of Ganciclovir to Prevent Cytomegalovirus Infectionin D+/R+ Renal Allograft Recipients

Objective:To assess the efficacy and tolerability of ganciclovir to prevent cytomegalovirus (CMV)infection after renaltransplantation.Methods:93 D+/R+ renal allograft recipients were given Prophylactic treatment of ganciclovir, and the incidence ofCMV infection and the time of infection and adverse event in 1year was observed.Results:In D+/R+ renal allograft recipients who werereceived ganciclovir prophylaxis, the incidence of CMV infection were 28 %, and the time to first viremia was 231.3 d. The incidence ofserious adverse events was 45.1 %.Conclusion:Ganciclovir prophylaxis significantly reduces CMV infection in D+/R+ renal allograftrecipients. However, it needs further studies in RCT.